MEDANTA
GLOBAL HEALTH LIMITED
Each stock's 10,000-path forecast, rendered as light.
GLOBAL HEALTH LIMITED (MEDANTA) Stock Analysis & Case Study
Is MEDANTA a good buy? The data-driven verdict.
GLOBAL HEALTH LIMITED (MEDANTA) trades at ₹1,456,on the numbers it mixed signals, a Downstox Snapshot Score of 49/100.
On the numbers, GLOBAL HEALTH LIMITED (MEDANTA) mixed signals, a Downstox Snapshot Score of 49/100, weighing expensive at 68.4× earnings, ROE of 15.2%, a 60% model probability of trading higher in a year. Below: the full bull case, bear case, sector-relative valuation, and a probability-weighted price target for 2027-2031.
Last updated . Data snapshot for research, not investment advice.
MEDANTA fundamentals at a glance, PE, PB, ROE, ROCE, market cap, dividend yield
How MEDANTA ranks against the 2,373 companies in our screener
- MEDANTA's market cap of 39,137 Cr ranks in the 90th percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- MEDANTA's book value of ₹147 ranks in the 63rd percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- MEDANTA's promoter holding of 33.0% ranks in the 10th percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- MEDANTA's 3-year profit (PAT) growth of 20.0% ranks in the 57th percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- MEDANTA's 3-year revenue growth of 18.0% ranks in the 69th percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- MEDANTA's debt-to-equity ratio of 0.30x is lower than 51% of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
Is MEDANTA overvalued? MEDANTA P/E vs peers
MEDANTA trades at 68.4× earnings. We don't have a verified sector peer group for this stock yet, so no sector peer median or peer comparison table is shown here. Showing one anyway would compare it against an arbitrary set of large-cap names, not real sector peers.
MEDANTA share price target 2027, 2028, 2029, 2030, 2031, a probability view
Unlike a single guessed number, this is a probability-weighted range from a 10,000-path Monte-Carlo simulation on 3.7y of MEDANTA history (34%/yr drift, 31%/yr volatility).
| Year | Low (P10) | Median target (P50) | High (P90) | Upside vs today |
|---|---|---|---|---|
| MEDANTA 2027 | ₹1,059 | ₹1,574 | ₹2,339 | +8% |
| MEDANTA 2028 | ₹973 | ₹1,702 | ₹2,977 | +17% |
| MEDANTA 2029 | ₹921 | ₹1,841 | ₹3,680 | +26% |
| MEDANTA 2030 | ₹891 | ₹1,990 | ₹4,447 | +37% |
| MEDANTA 2031 | ₹887 | ₹2,152 | ₹5,225 | +48% |
Median (P50) is the central estimate; the P10-P90 band is the 80% confidence range. Probabilities, not promises.
What is the probability MEDANTA goes up, or doubles?
The bull case for MEDANTA
- MEDANTA's return on equity of 15.2% ranks in the 72nd percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- A 10,000-path probability model puts a 60% chance the price is higher in a year, with a median target of ₹1,574 (+8%).
- Upside scenario: the model's optimistic (P90) 3-year path reaches ₹3,680.
The bear case & risks
- MEDANTA's P/E of 68.4x is lower than 17% of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- A steep 9.9× price-to-book means most of the value is intangible/expectations, not assets on the books.
- Downside scenario: the model's pessimistic (P10) 3-year path falls to ₹921.
MEDANTA volatility & expected range, how bumpy is the ride?
Over the last 3.7 years MEDANTA compounded at 34%/year with annualized volatility of 31%. That volatility implies a 1-year 80% range of ₹1,059-₹2,339, the honest backbone behind any single price target.
MEDANTA price forecast, the full 60-month probability fan
MEDANTA price probability fan
Each band shows where 10,000 simulated paths land. The wider the fan, the more uncertainty.
Probability of key outcomes
What are the odds MEDANTA hits common targets within the simulated horizon?
Full multi-horizon detail on the MEDANTA price target & forecast page.
MEDANTA Piotroski F-Score: 6/8, how financially strong is it?
The Piotroski F-Score grades financial strength on profitability, leverage and efficiency checks. Downstox scores the eight checks it can verify from published filings, so 8 is full marks. MEDANTA scores 6/8, mixed financial health.
MEDANTA MTF margin & leverage across 10 brokers
Margin Trading Facility lets you buy MEDANTA with part of the capital. Lower margin % = higher leverage. Rates compared across 10 brokers (no competitor publishes this):
| Broker | Margin required | Approx. leverage |
|---|---|---|
| Upstox | 29.41% | 3.4× |
| ZerodhaCHEAPEST | 29.38% | 3.4× |
| Groww | 29.43% | 3.4× |
| Dhan | 30.00% | 3.3× |
| Kotak Neo | 30.03% | 3.3× |
| Paytm Money | 29.45% | 3.4× |
| Pocketful | 29.58% | 3.4× |
| Anand RathiCHEAPEST | 29.38% | 3.4× |
| Bajaj Broking | 31.00% | 3.2× |
| Share India | 29.43% | 3.4× |
Compare every broker on the MEDANTA MTF page.
About GLOBAL HEALTH LIMITED: sector, index & market-cap context
GLOBAL HEALTH LIMITED (MEDANTA) is a mid-cap NSE-listed company, and a constituent of the Nifty 500 index, with a market capitalisation of ₹39,137 Cr. See more stocks on our screener.
How the MEDANTA Snapshot Score & forecast are built
The Downstox Snapshot Score is a transparent, rules-based read of GLOBAL HEALTH LIMITED's public fundamentals plus a statistical forecast, not an analyst opinion. It rewards low-to-fair valuation, high ROE/ROCE, a strong Piotroski F-Score, a dividend, low volatility and a favourable probability of upside; it penalises rich valuations, weak capital efficiency, a low F-Score and high volatility. The price target is a 10,000-path Monte-Carlo simulation on real historical volatility, a distribution, not a single guess. The bull and bear cases are generated from the same data, so you always see both sides.
This is information, not investment advice. Do your own due diligence and consult a SEBI-registered adviser before investing.
MEDANTA analysis, FAQs
Is GLOBAL HEALTH LIMITED (MEDANTA) a good buy?
On the numbers, GLOBAL HEALTH LIMITED (MEDANTA) mixed signals, a Downstox Snapshot Score of 49/100, weighing expensive at 68.4× earnings, ROE of 15.2%, a 60% model probability of trading higher in a year. This is a data snapshot for research, not investment advice.
Is MEDANTA overvalued or undervalued?
MEDANTA trades at 68.4× earnings, expensive versus the ~22× long-run Nifty average.
What is the MEDANTA share price target for 2031?
MEDANTA's probability-weighted 2031 median target is ₹2,152, with an 80% range of ₹887-₹5,225 (10,000-path Monte-Carlo).
What is the probability MEDANTA doubles in 5 years?
The modelled probability of MEDANTA reaching ₹2,911 (2×) within 5 years is 33%.
What is the bull case for MEDANTA?
MEDANTA's return on equity of 15.2% ranks in the 72nd percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026. A 10,000-path probability model puts a 60% chance the price is higher in a year, with a median target of ₹1,574 (+8%).
What are the risks in MEDANTA?
MEDANTA's P/E of 68.4x is lower than 17% of the 2,373 NSE companies in our screener, as of 9 Aug 2026. A steep 9.9× price-to-book means most of the value is intangible/expectations, not assets on the books.